Search

Your search keyword '"Michela Ansuinelli"' showing total 27 results

Search Constraints

Start Over You searched for: Author "Michela Ansuinelli" Remove constraint Author: "Michela Ansuinelli"
27 results on '"Michela Ansuinelli"'

Search Results

1. Tyrosine kinase inhibitor discontinuation in non-allografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study

3. A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol

4. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

5. ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings

6. Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases

7. Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse

8. Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

9. Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia

10. Author response for 'Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia'

11. Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia

12. a multicenter total therapy strategy for de novo adult philadelphia chromosome positive acute lymphoblastic leukemia patients final results of the gimema lal1509 protocol

13. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia

14. New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia

15. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?

16. Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy

17. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimale residual disease-oriented GIMEMA LAL1913

18. BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant

19. Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

20. Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

21. PS935 APPLICABILITY OF DROPLET DIGITAL PCR (DDPCR) FOR MINIMAL RESIDUAL DISEASE MONITORING (MRD) IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

22. Primary mediastinal large B-cell lymphoma

23. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors

24. Peripheral T-Cell Lymphomas (PTCL) Treated With Or Without Upfront Autologous Stem Cell Transplantation: Results Of a Retrospective Single Center Analysis

25. The Neutrophil/Lymphocyte Ratio (N/L) Is a Prognostic Marker in Patients with Diffuse Large B Cell Lymphoma: A Prospective Study from the Lazio Lymphoma Registry

26. Peripheral T-Cell Lymphomas Not Otherwise Specified: Potential Novel Molecular Entities Based on Both Tumor and Microenvironment Cellular Components

27. Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results

Catalog

Books, media, physical & digital resources